|
Long-term Safety Performance of Fexofenadine in Asthma Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Long-term Safety Performance of Fexofenadine in Asthma conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Long-term Safety Performance of Fexofenadine in Asthma Clinical research trials and Long-term Safety Performance of Fexofenadine in Asthma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Long-term Safety Performance of Fexofenadine in Asthma. Long-term Safety Performance of Fexofenadine in Asthma Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Long-term Safety Performance of Fexofenadine in Asthma clinical trial. Subjects often receive the most expert healthcare possible for their Long-term Safety Performance of Fexofenadine in Asthma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Long-term Safety Performance of Fexofenadine in Asthma  Long-term Safety Performance of Fexofenadine in Asthma
Long-term Safety Performance of Fexofenadine in Asthma
For Condition: Asthma
Status: No longer recruiting
Sponsor(s): Aventis Pharmaceuticals ,
Synopsis: The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma
Details: The incidence of respiratory allergy in the US has increased gradually over the past several years, and current estimates suggest that allergic rhinitis and bronchial asthma affect approximately 20% and 5% of the population, respectively. Rhinitis and asthma frequently coexist, and large-scale population surveys indicate that up to 38% of subjects with rhinitis have asthma, and up to 78% of subjects with asthma have chronic nasal symptoms. Safety concerns with the increased use of inhaled corticosterioids, the heterogeneity of the disease, and poor compliance with asthma medication regimens, point to the need for the development of safe and convenient oral therapies for asthma. Oral leukotriene receptor antagonists (eg montelukast) are the latest class of inflammation-modulating asthma drugs and appear to cause fewer long-term side effects than systemic corticosteroids and reduce the need for shorter-acting bronchodilator reliever medicines. However variability in response between patients has been observed and clinical experience with these agents is still limited. Histamine is an important chemical mediator of inflammation in asthma. The benefits of antihistamine treatment in patients with mild to moderate asthma have been well documented, however their clinical use has been previously limited due to the high doses required for efficacy and their associated side effects including sedation and cognitive impairment. Recent evidence indicates that in addition to H1-receptor antagonism, some of the newer nonsedating, non-impairing antihistamines appear to possess various anti-inflammatory properties at concentrations achieved at therapeutic dosages suggesting an additional benefit of these drugs in the management of allergic diseases and asthma. The purpose of this study is to assess the long-term safety performance of fexofenadine compared to montelukast in subjects with asthma.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 12 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Males and non-pregnant, non-breastfeeding females 12 through 80 years of age - FEV1 in the context of this study is greater than 40% and not less or equal to 87% of predicted values for subjects not currently taking ICS and greater than 40% and not less or equal to 95% for those subjects taking ICS at Visit 1 and/or Visit 2 (and no albuterol use within 6 hours prior to spirometry) - Improvement in FEV1 of at least 12% of predicted value and at least 200ml within 15 to 30 minutes of inhaling 2 puffs of albuterol 90mcg/actuation demonstrated at study entry OR documented during the previous 12 months at the study site. - Use of a short-acting, beta-agonist inhaler to treat asthma symptoms on an average of at least 2 days per week during the previous 2 weeks (greater than or equal to 4 days total during the previous 2 weeks, excluding prophylactic use). Exclusion criteria: - Otherwise healthy
Total Enrollment: 1200
Location and Contact Information:
Aventis Pharmaceutical Inc.
Bridgewater, New Jersey, 08807
United States
Additional Information:
Study ID Numbers: M016455P/3003;
Study Start Date: February 2002
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045955
Other Asthma Studies:
1. Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma
2. Activation and Function of Eosinophils in Conditions with Blood or Tissue Eosinophilia
3. Community Based Study on Occupational Asthma
4. Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
5. Development and Evaluation of Community Asthma Program
Related Studies:
Other Asthma Clinical Trials
Other New Jersey Clinical Trials
Other Bridgewater Clinical Trials
Long-term Safety Performance of Fexofenadine in Asthma
|
|
|
|
|
|
|
|
